- Rapport Therapeutics conducted a Phase 2 trial of RAP-219 for bipolar mania.
Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for bipolar mania. The company stated the results were positive but did not release detailed data. Further information is expected.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.